Development and desiccation treatment of somatic embryos induced from transgenic alfalfa plants.

<p>A. Development of somatic embryos from a transgenic plant; B. Somatic embryos after ABA treatment. C. Somatic embryos after desiccation treatment. D. Germination of desiccated embryos. E. Development of plants from desiccated somatic embryos. F. Development of plants from somatic embryos without desiccation. G. Recovery of plants from desiccated somatic embryos in a green house. H. GUS expression in a plant developed from an embryo without desiccation; I. GUS expression in a plant developed from desiccated embryo; J. No GUS expression in control plant.</p

Germination of somatic embryos with and without desiccation treatment of different transgenic alfalfa lines.

<p>Germination of somatic embryos with and without desiccation treatment of different transgenic alfalfa lines.</p

Infection, clearance and survival rates of each treatment group (excluding unexposed controls) following exposure to <i>Batrachochytrium dendrobatidis</i> (<i>Bd</i>).

<p>“Inoculated” frogs were previously exposed and infected with <i>Bd</i> and cleared of infection with itraconazole prior to exposure, “Treated” frogs were not initially exposed to <i>Bd</i> but were treated with itraconazole prior to exposure, “Naïve” frogs were not exposed nor treated prior to exposure.</p

Flow chart of experimental treatment groups.

<p>Flow chart of experimental treatment groups.</p

Relationship of Vitamin D status with progression to HIV disease stage III or IV during follow-up.

<p>Relationship of Vitamin D status with progression to HIV disease stage III or IV during follow-up.</p

Vitamin D Status and HIV Disease Progression and Mortality among HIV-infected Women.

1<p>All multivariate models adjusted for age, treatment regimen, CD4 T-cell counts at baseline, and HIV disease stage at baseline.</p>2<p>% (N): Percentage of cases (Total number).</p>3<p>p-values obtained from Cox regression models.</p

Vitamin D Status and T-cell Subset Counts in HIV-infected Women (n = 636).

1<p>Time-adjusted models adjusted for length of interval between two successive measurements and time since randomization.</p>2<p>All multivariate models adjusted for age, treatment regimen, and HIV disease stage at baseline.</p

Relationship of vitamin D status with all-cause mortality among HIV-infected women in Tanzania.

<p>Relationship of vitamin D status with all-cause mortality among HIV-infected women in Tanzania.</p

Baseline Characteristics of Women enrolled in the trial with available vitamin D levels (N = 884).

*<p>SD: Standard Deviation.</p

Vitamin D Status and Hematological Outcomes.

1<p>p-values are from Cox Regression Models.</p>2<p>% (N): Percentage of cases (Total number).</p>3<p>Severe: Hypochromasia ≥2+ and microcytic cells observed.</p>4<p>Moderate and above: Hypochromasia ≥1+ and microcytic cells observed.</p>5<p>Mild and above: Hypochromasia ≥1+.</p>6<p>All multivariate models adjusted for age, CD4 T-cell counts, HIV disease stage at baseline, and regime received.</p